menu ☰
menu ˟

FDA approves Lynparza, first treatment for BRCA-mutated breast cancer

13 Jan 2018
The FDA expanded the indication of olaparib to include patients with germline BRCA-mutated, HER-2-negative metastatic breast cancer who were previously treated with chemotherapy.Olaparib (Lynparza; AstraZeneca, Merck) — a poly ADP-ribose polymerase...

Click here to view the full article which appeared in Hematology Oncology

IPH Logo